Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2014 · 10-Q
Revenue$566.00K$566.00K+35.1% vs Q3 2013 Net Income-$35.28M-$35.28MN/M vs Q3 2013 EPS Diluted-$0.34-$0.34N/M vs Q3 2013 Operating Income-$33,677,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$25,669,000N/M Margins · derivedOperating margin-5950.0%+3676.7 pt vs Q3 2013
Net margin-6233.6%+3431.8 pt vs Q3 2013
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end